Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 8/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5756448 | 0.91 | ILK (0.52) | DRD3DRD4DRD2S1PR1S1PR3 | |
| SCHEMBL5758629 | 0.90 | ILK (0.51) | DRD3DRD4DRD2S1PR1S1PR3 | |
| SCHEMBL5757116 | 0.86 | PDCD1 (0.50) | DRD3DRD4S1PR1S1PR3NPC1 | |
| SCHEMBL5755342 | 0.83 | ILK (0.51) | DRD3DRD4DRD2S1PR1S1PR3 | |
| SCHEMBL5754098 | 0.81 | ILK (0.56) | DRD3DRD4DRD2S1PR1S1PR3 | |
| SCHEMBL25111049 | 0.79 | NPC1 (0.55) | DRD3DRD4DRD2NPC1RAB9A | |
| SCHEMBL5756891 | 0.77 | ILK (0.45) | DRD3DRD4DRD2S1PR1S1PR3 | |
| SCHEMBL5759036 | 0.77 | ILK (0.53) | S1PR1S1PR3GAANPC1RAB9A | |
| SCHEMBL5755144 | 0.76 | POLB (0.52) | S1PR1MGAMGAASIMGAM2 | |
| SCHEMBL5756434 | 0.75 | APP (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | claimed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | claimed |
| EP-1539723-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016600-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ITK, WEE2, WEE1 | DRD3 3213/4885DRD4 4169/4885DRD2 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.